Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
Technology appraisal guidance
Reference number: TA857
Published:
Evidence
Review and download supporting evidence. Includes the full guideline if available.